Clovis inks deal with Bristol-Myers Squibb
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has entered into a clinical agreement with Bristol-Myers Squibb (NYSE: BMY).
The two companies will test the combination of Clovis’ Rubraca drug with Bristol-Myer Squibb’s immunotherapy Opdivo across multiple tumor types.
The Phase 3 studies will be conducted in advanced ovarian cancer and advanced triple-negative breast cancer. The partnership will also include a Phase 2 clinical trial in metastatic prostate cancer.
SPONSORED CONTENT
How dispatchable resources enable the clean energy transition
Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).
Boulder-based Clovis will be in charge of running the ovarian cancer tests while Bristol-Myers operates the prostate and breast cancer studies.
All three tests should be started before the end of the year.
Clovis’ stock fell over the weekend, down from $98 when the market closed on Friday to $92.40 per share when the market opened on Monday. Stock has steadily declined since then and was at $85.20 at time of publication.
